TÜBINGEN, Germany, May 10, 2021 / B3C newswire / -- The senior management of Acousia Therapeutics GmbH will be discussing the company’s approach to translational development of small molecule drug candidates for the treatment of hearing loss at the upcoming Inner Ear Disorders Therapeutics Summit (May 25-27, 2021) and the Bellucci Symposium on Hearing Research (June 3-4, 2021). Furthermore, the company will be presenting and engaging in partnering discussions at the European Bio€quity Meeting (May 17-21).
„We are advancing rapidly towards clinical testing of our first development candidate ACOU085 in patients with age-related hearing loss.“ said CEO Tim Bölke.
Professor Hubert Löwenheim, chair of the Tübingen University ENT clinic and Acousia Therapeutics co-founder added: „Despite the overwhelming burden of hearing loss for patients and society, the quest for drug therapies against hearing loss remains one of the most under-resourced areas in drug discovery.”
„The heterogeneity of etiologies and lack of standards for drug development in the field present an exciting challenge in delivering novel solutions for patients suffering from hearing loss “said Chief Development Officer Jonas Dyhrfjeld-Johnsen. „We believe that a robust understanding of the hearing-loss pathophysiology combined with solid translational principles opens the door to preserving and enhancing the natural hearing of patients in an individualized/personalized manner.“
Acousia Therapeutics GmbH is developing a series of small molecule drug candidates for local and systemic treatment of different forms of hearing loss. While the start of the ACOU085 phase 1 study in patients with age-related hearing loss is planned for the second half of 2021, next generation drug candidates are being thoroughly characterized in a range of both specialized and standard preclinical models and assays.
About Acousia Theraputics GmbH
Privately-held Acousia Therapeutics GmbH is based in Tübingen, Germany. The company is dedicated to the identification and development of small molecules for effective prevention and treatment of hearing loss. Acousia is developing drugs for local and systemic application. The company was founded 2012 by three partners: Prof. Dr. Hubert Löwenheim (chair of otolaryngology, University Clinic of Tübingen), EMC Microcollections GmbH (EMC), and Boehringer Ingelheim Venture Fund GmbH (BIVF), followed by Axxam, Bregua, Creathor, KfW and LBBW-Venture in further financing rounds.
Contact
Tim Boelke, M.D.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Published by B3C newswire